angel capital instead of venture capital

Clarisonic

Sector
Beauty & Wellness / Consumer Device
headquarters
Redmond, Washington, USA
Stage
Seed - 2001
$65K
Reported Keiretsu seed capital
13x
Reported return on the seed position
L’ORÉAL
Acquired by L’Oréal USA in December 2011

Keiretsu Forum provided seed capital to Pacific Bioscience Laboratories at its earliest stage, and the company went on to pass $100M in annual revenue without ever raising an institutional venture round.

Scaled to $105M in revenue and a L’Oréal exit without a single VC round

Clarisonic sonic skin-care devices developed by Pacific Bioscience Laboratories

01

The company

Clarisonic — the sonic skin-cleansing brush that became a category-defining product in prestige skincare — was developed by Pacific Bioscience Laboratories, founded in Redmond, Washington in 2001 by David Giuliani, Robb Akridge, Steve Meginniss, Ward Harris and Ken Pilcher. Giuliani was already a proven operator in the category, having co-founded Optiva Corporation, maker of the Sonicare electric toothbrush, and sold it to Philips; Pilcher, the lead inventor on Clarisonic, came from NASA Space Shuttle avionics and medical electronics.

02

The investment

Keiretsu Forum is documented as having provided seed capital for Pacific Bioscience Laboratories at its earliest stage. What makes Clarisonic distinctive in the portfolio is what never happened next: Giuliani did not raise traditional venture capital at any point in the company’s life. The product launched in 2004 and grew into the market leader in sonic skin-care technology entirely on angel financing.

03

The journey

The company scaled to more than $100 million in annual revenue — roughly $105 million in the fiscal year before its sale — and about 300 employees without a single institutional VC round diluting the capitalisation table. The $65,000 figure commonly cited for Keiretsu Forum’s check size is consistent with a seed-stage, per-member-scale investment rather than a lead institutional round: chapter-level member commitments typically range from roughly $250,000 to $2 million per opportunity, but early seed checks from individual members or small syndicates inside a chapter are frequently much smaller, which fits this figure.

On the numbers: Wikipedia and contemporaneous trade press confirm that Keiretsu Forum provided Clarisonic’s seed capital and that the 2011 acquisition was a strong outcome for early investors, but neither the exact check size nor the return multiple appears in any public source — L’Oréal never released deal terms. Both the $65,000 investment and the 13x return should therefore be read as sourced from Keiretsu Forum’s own internal reporting rather than independently confirmed.

  1. 2001

    Pacific Bioscience Laboratories founded

  2. 2004

    Clarisonic launches

  3. 2011

    ~$105M revenue, ~300 employees

  4. December 2011

    Acquired by L’Oréal USA

04

The outcome

L’Oréal USA announced its acquisition of Pacific Bioscience Laboratories on November 10, 2011, and the deal closed that December. The purchase price was never publicly disclosed by either party, but contemporaneous trade coverage described it as “a good outcome for early investors” — language consistent with a double-digit return multiple. L’Oréal initially committed to keeping the Clarisonic brand and the Redmond operation intact as an innovation centre, and later discontinued the brand in July 2020 amid competition from lower-cost devices, nearly nine years after the acquisition and with no bearing on the return investors had already realised.

05

Network Impact

Clarisonic is the cleanest case in the portfolio for angel capital as a genuine substitute for venture capital rather than a bridge to it. Because Giuliani deliberately avoided VC funding for the life of the company, the Keiretsu Forum seed check was never diluted or subordinated by a later institutional preferred-stock round — the angel money that started the company was still on the capitalisation table, on the same terms, when L’Oréal wrote the acquisition check almost a decade later.

That is the best-case outcome of the model: early risk capital capturing the full upside of a category-creating product without ever being crowded out by larger, later investors.

06

Sources

Building the next great company?

Whether you’re raising capital or looking for your next investment opportunity, connect with Keiretsu Forum MENA.

Apply as a Startup